Trump signs psychedelics EO

President Trump signed an executive order on April 18 directing federal agencies to speed review of certain psychedelic drugs for serious mental illness. (whitehouse.gov) The order tells the Food and Drug Administration to prioritize psychedelic drugs that already have Breakthrough Therapy designation, a status the agency uses to speed development when early evidence suggests a drug may outperform existing treatment. It also tells the Food and Drug Administration and Drug Enforcement Administration to create a pathway for some patients to access investigational psychedelics, including ibogaine, under the federal Right to Try law. (whitehouse.gov; fda.gov) The White House said the order also requires the Department of Health and Human Services to put $50 million from the Advanced Research Projects for Health into matching state investments in psychedelic research. It also directs federal health officials to work with the Department of Veterans Affairs and private groups to expand clinical trial participation and evidence collection. (whitehouse.gov) The administration tied the move to veteran suicide and treatment-resistant illness. The executive order says more than 6,000 veterans have died by suicide each year for more than 20 years, and Veterans Affairs reported 6,407 veteran suicides in 2022, the most recent year in its 2024 annual report. (whitehouse.gov; va.gov) Psychedelics are drugs that can sharply alter perception, mood, and sense of time. In this order, the focus is not broad legalization but moving a narrow set of experimental treatments through federal review faster for patients with severe depression, substance use disorder, and other conditions that have not improved with standard care. (whitehouse.gov; fda.gov) Ibogaine became the most visible drug in the announcement. The Associated Press reported that Trump’s Oval Office guests included Health and Human Services Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and retired Navy SEAL Marcus Luttrell, whose advocacy helped push the issue inside conservative political circles. (ksat.com) The drugs covered by the order are not approved medicines yet. Ibogaine remains a Schedule I drug under federal law, and published reviews have flagged heart-rhythm risks and drug interactions as major barriers to wider clinical use. (ksat.com; nih.gov) That leaves the next fight with regulators, not politicians. The order can speed agency timelines and trial access, but the Food and Drug Administration still has to decide whether any psychedelic treatment is safe and effective enough to approve. (whitehouse.gov; fda.gov)